Earnings Summary

Hutchison China Meditech Limited’s revenue jumped 36.24% since last year same period to $152.84Mn in the Q4 2023. On a quarterly growth basis, Hutchison China Meditech Limited has generated 0.18% jump in its revenue since last 3-months.

Hutchison China Meditech Limited’s net profit jumped 113.03% since last year same period to $12.9Mn in the Q4 2023. On a quarterly growth basis, Hutchison China Meditech Limited has generated 138.07% jump in its net profits since last 3-months.

Hutchison China Meditech Limited’s net profit margin jumped 109.57% since last year same period to 8.44% in the Q4 2023. On a quarterly growth basis, Hutchison China Meditech Limited has generated 138% jump in its net profit margins since last 3-months.

Hutchison China Meditech Limited’s earning per share (EPS) estimates for the current quarter stand at -1.08 - a -2560.14% fall from last quarter’s estimates.

Hutchison China Meditech Limited’s earning per share (EPS) estimates for the current year stand at -1.08.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Hutchison China Meditech Limited’s return on assets (ROA) stands at -0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Hutchison China Meditech Limited’s return on equity (ROE) stands at -0.05.